Sorafenib in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with metastatic
breast cancer. Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary
for their growth and by stopping blood flow to the tumor.